ibrutinib
janssen,abbvie
['ibru']
re second malignancies
need to clarify whether the denominator calculated for the ibrutinib arm matches that of the placebo arm (ie time on treatment) before can make definitive claims #17icml 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem